Search results for: 'Channel Profitability Study'

The global biopharma patient access market is undergoing a structural shift as specialty medicines make downstream commercialization more complex and strategically important. Patient access is no longer limited to reimbursement support or hub services; it is becoming a commercialization control layer spanning authorization, affordability, therapy i...

This study focuses on emerging pharmacological and non-pharmacological strategies in the treatment of obesity, as well as evolving new paradigms for the future. It describes the contribution of incretin-based therapies, particularly GLP-1 receptor agonists and their multi-agonist counterparts, which provide robust effects on weight loss and metabol...

In this analysis, Frost & Sullivan identifies and defines the leading trends shaping the global pharmaceutical landscape. The study period is 2022–2030, with 2024 as the base year and 2025–2028 as the forecast period. The geographic scope includes 5 regions: North America, Latin America (LATAM) and the Caribbean, Asia-Pacific (APAC), Europe, and th...

There have been increasing incidences of rare ophthalmic diseases (e.g., retinitis pigmentosa, Stargardt disease, Leber congenital amaurosis) and prevalent diseases (e.g., age-related macular degeneration [AMD], geographic atrophy). While clinicians have used small molecules as the conventional therapeutic modality to manage these diseases, the urg...

The global pharmaceutical market is projected to reach approximately $1.72 trillion in 2026, with large molecules driving most incremental growth while small molecules remain the sector’s cash flow base. The current growth cycle concentrates on cardiometabolic and oncology, led by GLP-1 platforms and antibody–drug conjugates (ADCs). Competitive adv...

The report explores the transformation of obesity care from generalized BMI-based treatment to AI-enabled precision metabolic management. The study highlights how obesity is increasingly recognized as a heterogeneous, multi-pathway disease influenced by genetic, neurobehavioral, metabolic, and environmental factors, requiring personalized therapeut...

Artificial intelligence is becoming increasingly relevant to antibody discovery and immunotherapy development, supporting target identification, de novo antibody design, antibody engineering, clinical intelligence, and bioprocessing. Advances in generative AI, protein language models, diffusion models, and structure-based models are expanding the u...

27 Sep 2017  |  Africa  |  Market Research

East African Pharmaceutical Market, Forecast to 2021

Generic Pharmaceutical Products Continue to Dominate with Increased Foreign Direct Investment by Asian Manufacturers

Infographics

×

Pharmaceutical markets in Sub-Saharan Africa are experiencing rapid growth as governments and healthcare providers battle with their respective burdens of disease. The continent has one of the highest burdens of disease, such as HIV, malaria, and tuberculosis, yet has limited healthcare resources and spending. As such there are great opportunities ...

19 Sep 2018  |  North America  |  Market Research

Global Biologics Contract Development and Manufacturing Organization (CDMO) Market, Forecast to 2022

Investments in Single Use/Disposable Technologies to Capitalize on Growth Opportunities in High-value Low-volume Biologics

Infographics

×

Key Issues Addressed

The global pharmaceutical industry is evolving with the rising need for novel therapies in the changing disease landscape. As a result of rising prevalence of chronic infectious diseases as well as growing cancer incidence, market needs are shifting from traditional small molecules to large molecules. This study presents an overview of the global b...